Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma

International Journal of Cancer

Volumn 126, Issue 9, 2010, Pages 2112-2122

  Coufal, Monique ^a   Invernizzi, Pietro ^b   Gaudio, Eugenio ^c   Bernuzzi, Francesca ^b,d   Frampton, Gabriel A ^a   Onori, Paolo ^e   Franchitto, Antonio ^c   Carpino, Guido ^f   Ramirez, Jonathan C ^a   Alvaro, Domenico ^c   Marzioni, Marco ^g   Battisti, Guido ^c   Benedetti, Antonio ^g   DeMorrow, Sharon ^a,h  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF L'AQUILA   (Italy)

^f UNIVERSITY OF ROME FORO ITALICO   (Italy)

^g UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^h SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Biliary cancer; Biogenic amines; Dopa decarboxylase; Monoamine oxidase A; Tyrosine hydroxylase

Indexed keywords

3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 4 RECEPTOR ANTAGONIST; DOPAMINE RECEPTOR BLOCKING AGENT; L 741626; MESSENGER RNA; METHYLDOPA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINE RELEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR BIOPSY; ANIMAL; BAGG ALBINO MOUSE; BILE DUCT TUMOR; DRUG SCREENING; INTRAHEPATIC BILE DUCT; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; DOPAMINE; HUMANS; MALE; METHYLDOPA; MICE; MICE, INBRED BALB C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949892844     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24909     Document Type: Article

References (44)

1. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology 2003;37: 961-969
2. Blechacz B, Gores GJ. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: utility and mechanistic insight. J Hepatol 2008;49: 160-162
3. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12:131-50, ix.
4. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 2005;41: 5-15.
5. Fava G, Alpini G, Rychlicki C, Saccomanno S, DeMorrow S, Trozzi L, Candelaresi C, Venter J, Di Sario A, Marzioni M, Bearzi I, Glaser S, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res 2008;68:6752-6761
6. Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F, Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D
7. Lee SP, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008;68:9184-9193
8. DeMorrow S, Francis H, Gaudio E, Venter J, Franchitto A, Kopriva S, Onori P, Mancinelli R, Frampton G, Coufal M, Mitchell B, Vaculin B, et al. The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathway. Am J Physiol Gastrointest Liver Physiol 2008;295:G1150-8.
9. Shih JC, Chen K, Ridd MJ. Role of MAO A and B in neurotransmitter metabolism and behavior. Pol J Pharmacol 1999;51: 25-29
10. Callier S, Snapyan M, Le Crom S, Prou D, Vincent JD, Vernier P. Evolution and cell biology of dopamine receptors in vertebrates. Biol Cell 2003;95:489-502.
11. Saha B, Mondal AC, Basu S, Dasgupta PS. Circulating dopamine level, in lung carcinoma patients, inhibits proliferation and cytotoxicity of CD4\+ and CD8\+ T cells by D1 dopamine receptors: an in vitro analysis. Int Immunopharmacol 2001;1: 1363-1374
12. Saha B, Mondal AC, Majumder J, Basu S, Dasgupta PS. Physiological concentrations of dopamine inhibit the proliferation and cytotoxicity of human CD4\+ and CD8\+ T cells in vitro: a receptor-mediated mechanism. Neuroimmunomodulation 2001;9:23-33.
13. Basu S, Dasgupta PS. Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 1999;44:916-921
14. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 2004;10:4349-4356
15. Ivan G, Szigeti-Csucs N, Olah M, Nagy GM, Goth MI. Treatment of pituitary tumors: dopamine agonists. Endocrine 2005;28:101-110
16. Chan AS, Ng LW, Poon LS, Chan WW, Wong YH. Dopaminergic and adrenergic toxicities on SK-N-MC human neuroblastoma cells are mediated through G protein signaling and oxidative stress. Apoptosis 2007;12:167-179
17. Knuth A, Gabbert H, Dippold W, Klein O, Sachsse W, Bitter-Suermann D, Prellwitz W, Meyer zum Buschenfelde KH. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985;1:579-596
18. Shimizu Y, Demetris AJ, Gollin SM, Storto PD, Bedford HM, Altarac S, Iwatsuki S, Herberman RB, Whiteside TL. Two new human cholangiocarcinoma cell lines and their cytogenetics and responses to growth factors, hormones, cytokines or immunologic effector cells. Int J Cancer 1992;52:252-260
19. Miyagiwa M, Ichida T, Tokiwa T, Sato J, Sasaki H. A new human cholangiocellular carcinoma cell line (HuCC-T1) producing carbohydrate antigen 19/9 in serum-free medium. In Vitro Cell Dev Biol 1989;25: 503-510
20. Storto PD, Saidman SL, Demetris AJ, Letessier E, Whiteside TL, Gollin SM. Chromosomal breakpoints in cholangiocarcinoma cell lines. Genes Chromosomes Cancer 1990;2:300-310
21. Grubman SA, Perrone RD, Lee DW, Murray SL, Rogers LC, Wolkoff LI, Mulberg AE, Cherington V, Jefferson DM. Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell lines. Am J Physiol 1994;266: G1060-70.
22. 2\+-dependent protein kinase C-alpha. J Hepatol 2001;34:284-291
23. DeMorrow S, Glaser S, Francis H, Venter J, Vaculin B, Vaculin S, Alpini G. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of fas and fas ligand to lipid rafts. J Biol Chem 2007;282:13098-13113
24. Bertoldi M, Dominici P, Moore PS, Maras B, Voltattorni CB. Reaction of dopa decarboxylase with alpha-methyldopa leads to an oxidative deamination producing 3,4-dihydroxyphenylacetone, an active site directed affinity label. Biochemistry 1998; 37:6552-6561
25. Kassack MU, Hofgen B, Decker M, Eckstein N, Lehmann J. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 2002;366:543-550
26. Bowery BJ, Razzaque Z, Emms F, Patel S, Freedman S, Bristow L, Kulagowski J, Seabrook GR. Antagonism of the effects of (\+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626. Br J Pharmacol 1996; 119:1491-1497
27. Yuan J, Chen X, Brodbeck R, Primus R, Braun J, Wasley JW, Thurkauf A. NGB 2904 and NGB 2849: two highly selective dopamine D3 receptor antagonists. Bioorg Med Chem Lett 1998;8:2715-2718
28. Bristow LJ, Kramer MS, Kulagowski J, Patel S, Ragan CI, Seabrook GR. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 1997;18:186-188
29. Fava G, Marucci L, Glaser S, Francis H, De Morrow S, Benedetti A, Alvaro D, Venter J, Meininger C, Patel T, Taffetani S, Marzioni M, et al. Gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 2005;65:11437-11446
30. Kapoor V, Chalmers J. Correlation between fall in blood pressure and in vivo amine release after alpha-methylDOPA. Eur J Pharmacol 1989;164:531-538
31. Sivagnanam G, Adithan C, Thakur LC, Raveendran R, Bapna JS. Alphamethyldopa analgesia: its possible mechanism of action. Arch Int Pharmacodyn Ther 1985; 277:168-176
32. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 2007;39:175-191
33. Awada SH, Grisham A, Woods SE. Large dopamine-secreting pheochromocytoma: case report. South Med J 2003;96:914-917
34. Tam V, Ng KF, Fung LM, Wong YY, Chan MH, Lam CW, Tam S. The importance of the interpretation of urine catecholamines is essential for the diagnosis and management of patient with dopamine-secreting paraganglioma. Ann Clin Biochem 2005;42:73-77
35. Yasunari K, Kohno M, Minami M, Kano H, Ohhira M, Nakamura K, Yoshikawa J. A dopamine-secreting pheochromocytoma. J Cardiovasc Pharmacol 2000;36 Suppl 2: S75-7.
36. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem 1994;40: 86-95.
37. Yang TT, Tsao CW, Li JS, Wu HT, Hsu CT, Cheng JT. Changes of dopamine content and cell proliferation by dexamethsone via pituitary adenylate cyclase-activating polypeptide in PC12 cell. Neurosci Lett 2007;426:45-48
38. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 2004;287:H1554-60.
39. Olvera-Cortes ME, Anguiano-Rodriguez P, Lopez-Vazquez MA, Alfaro JM. Serotonin/dopamine interaction in learning. Prog Brain Res 2008;172: 567-602.
40. Di Giovanni G, Di Matteo V, Pierucci M, Esposito E. Serotonin-dopamine interaction: electrophysiological evidence. Prog Brain Res 2008;172: 45-71.
41. Gonzalez-Burgos I, Feria-Velasco A. Serotonin/dopamine interaction in memory formation. Prog Brain Res 2008;172: 603-623
42. Trager C, Vernby A, Kullman A, Ora I, Kogner P, Kagedal B. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer 2008;123: 2849-2855
43. Meijer WG, Copray SC, Hollema H, Kema IP, Zwart N, Mantingh-Otter I, Links TP, Willemse PH, de Vries EG. Catecholamine-synthesizing enzymes in carcinoid tumors and pheochromocytomas. Clin Chem 2003; 49:586-593
44. Gilbert JA, Frederick LM, Ames MM. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res 2000;6:4365-4372